FOSUN PHARMA - An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

make any statement and expressly disclaim any liability for any damages whatsoever arising from or in reliance upon the whole or any part of the contents of this announcement. assumes no responsibility for any failure. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (a joint stock limited company incorporated in the People's Republic of China) (Stock code: 02196) Overseas regulatory announcement This announcement is made in accordance with Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. This is to set forth the "About Announcement on the Re-appointment of the Accounting Firm in 2026" is for reference only. By order of the board of directors Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Chairman Chen Yuqing China, Shanghai March 24, 2026 As at the date of this announcement, the executive directors of the Company are Mr. Chen Yuqing, Ms. Guan Xiaohui, Mr. Wen Deyong, Mr. Wang Kexin and Mr. Liu Yi; the Company The non-executive directors of the company are Mr. Chen Qiyu and Mr. Pan Donghui; the independent non-executive directors of the company are Mr. Yu Zishan, Mr. Wang Quandi, and Mr. Chen Mr. Penghui and Mr. Yang Yucheng; and the employee director of the Company is Ms. Yan Jia. *For identification only Securities code: 600196 Stock abbreviation: Fosun Pharma Number: Lin 2026-042 Shanghai Shanghai Fufu Xingxing Medical and Pharmaceutical ((Group)) Co., Ltd. Announcement on the renewal of the appointment of the accounting firm in 2002266 The Board of Directors of the Company and all directors hereby certify that the contents of this announcement do not contain any false records or misleading statements. The statements may contain many omissions or omissions, and we shall be legally responsible for the truthfulness, accuracy and completeness of its contents. . Important content reminder: Name of the domestic accounting firm to be re-appointed: Ernst & Young Hua Ming LLP (Special General Partnership) On March 24, 2026, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as "the Company") The 25th meeting of the 10th Board of Directors of the Company reviewed and approved the re-appointment of the Company’s accounting personnel in 2026 and the accounting firm’s remuneration in 2025, and plans to renew the appointment of Ernst & Young Hua Ming Accounting Firm (Special General Partnership) (hereinafter referred to as "Ernst & Young Hua Ming") is the company's 2026 domestic financial report and internal control (hereinafter referred to as "this renewal matter"), the proposed renewal of the domestic accounting firm is as follows: 11. Basic information about the accounting firm proposed to be appointed ((11)) Institutional information 1. Basic information Ernst & Young Hua Ming was established in September 1992 and completed its localization transformation in August 2012. It was transformed from a Sino-foreign joint venture The limited liability firm was transformed into a special general partnership firm. Ernst & Young Hua Ming is headquartered in Beijing. The registered address is Room 01-12, 17th Floor, Ernst & Young Building, Oriental Plaza, No. 1 East Chang'an Street, Dongcheng District, Beijing. As of December 31, 2025, Ernst & Young Hua Ming had 249 partners, and the chief partner was Mao An Mr. Ning. Ernst & Young Hua Ming has always focused on talent cultivation. As of December 31, 2025, it has There are more than 1,700 certified public accountants, including more than 1,700 practicing certified public accountants with experience in securities-related business services. There are 1,500 CPAs, and more than 550 CPAs have signed audit reports on securities services business. Ernst & Young Hua Ming's audited total business income in 2024 was RMB 5.71 billion, of which audit business income RMB 5.475 billion (including securities business income of RMB 2.369 billion). A-share listed companies in 2024 The company has a total of 155 annual report audit clients, with a total fee of RMB 1.189 billion, mainly involving manufacturing, financial Financial industry, wholesale and retail industry, mining industry, information transmission, software and information technology service industry and other industries. My Lord The company has 13 audit clients of listed companies in the same industry. 2. Investor protection capabilities Ernst & Young Hua Ming has good investor protection capabilities and has made professional risk provisions in accordance with relevant laws and regulations. insurance fund and purchase of professional insurance, which covers the Beijing head office and all branches. Provision of occupational risk funds The sum of the cumulative compensation limit of purchased professional insurance exceeds RMB 200 million. Ernst & Young Hua Ming has not existed in the past three years In the event of any civil liability resulting from civil litigation related to the conduct of the practice. 3. Integrity record In the past three years, Ernst & Young Hua Ming has been subject to supervisory and management measures three times and self-regulatory measures once due to its professional conduct. Subject to criminal penalties, administrative penalties and disciplinary sanctions. 19 practitioners have been punished for their professional conduct in the past three years 2 administrative penalties, 4 supervisory and management measures, 2 self-regulatory regulatory measures, 1 industry penalty; 2 practitioners The personnel have been subject to administrative supervision measures once each due to personal behavior in the past three years, which does not involve the practice quality of the audit project. According to relevant laws and regulations, the aforementioned matters will not affect Ernst & Young Hua Ming’s continued undertaking or execution of securities services. services and other businesses. ((22)) Project personnel information 1. Basic information The company's annual review project partner and first signing certified public accountant is proposed to be Ms. Zhang Lili. Zhang Lili He became a certified public accountant in 2007, started auditing listed companies in 1999, and started working in Ansu in 2007. Yong Huaming is practicing law and will start providing audit services to the company in 2024; in the past three years, he has signed 1 company/reviewed 1 company Annual reports/internal control audits of listed companies, involving industries including pharmaceutical manufacturing and wholesale industries. The second signing certified public accountant for the company's annual review project is proposed to be Mr. Fan Xianyu. Mr. Fan Xianyu in 2018 He became a certified public accountant in 2014, started auditing listed companies in 2014, and started practicing at Ernst & Young Hua Ming in 2019. industry, and will start providing audit services to the company in 2024; it has not signed the annual report/internal control audit of listed companies in the past three years. The project quality control reviewer is proposed to be Mr. Han Rui. Mr. Han Rui became a certified public accountant in 2006. He started auditing listed companies in 2010, started practicing at Ernst & Young Hua Ming in 2006, and started working as a principal in 2023. The company provides audit services and has signed/reviewed the annual reports/internal control audits of 2 domestic listed companies in the past three years, involving The industries covered include pharmaceutical manufacturing, Internet and related services. 2. The independence and integrity records of the above-mentioned relevant personnel The above-mentioned project partners, signing certified public accountants and quality control reviewers do not violate the "China Registration Accountant Independence Standards No. 1 and the Chinese Code of Professional Ethics for Certified Public Accountants regarding independence requirements situation, and has not been subject to criminal penalties, administrative penalties, administrative supervision measures or self-discipline supervision measures in the past three years situation. ((33)) Audit and accounting fees Fees for Ernst & Young Hua Ming to provide domestic financial reporting and internal control audit services to the Company in 2025 The expenses were RMB 2.8 million and RMB 650,000 respectively, which were consistent with the audit expenses of the previous year. Audit fees for this year Determined by comprehensive consideration of industry charges and the size of the company. 22. The procedures to be performed by the accounting firm that intends to renew the appointment 1. Discussion on the company’s renewal of the accounting firm in 2026 and the accounting firm’s remuneration in 2025 The proposal has been reviewed and approved by the second meeting of the Audit Committee of the 10th Board of Directors in 2026. reviewed, audited The Committee believes that: Ernst & Young Hua Ming has the necessary professional competence, investor protection capabilities, independence and integrity With good integrity status, we agree to this renewal matter and agree to submit the proposal to the board of directors for review. 2. After deliberation at the 25th meeting of the 10th board of directors of the company, the board of directors agreed and submitted it to the shareholders’ meeting Approved the proposal on the company's renewal of the accounting firm in 2026 and the accounting firm's remuneration in 2025. 3. This renewal of appointment still needs to be submitted to the company’s shareholders’ meeting for approval. 33. Prepare documents for future reference 1. Resolution of the Second Meeting of the Audit Committee of the Tenth Board of Directors in 2026 2. Resolution of the 25th meeting of the 10th Board of Directors Announcement is hereby made. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. board of directors March 24, 2026